Loading stock data…
$60.43-2.42 (-3.85%)
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases.
Vaxcyte, Inc. in the Healthcare sector is trading at $60.43 with a market capitalization of $8.8B. Wall Street consensus targets $117.30 (10 analysts), implying a +94.1% move over the next 12 months. The stock is currently 33% below its 52-week high of $90.75, remaining 6.7% above its 200-day moving average. On fundamentals, Piotroski 1/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 30 is oversold, raising the odds of a near-term bounce. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$302.78M↑ | -$345.85M↓ | -$274.28M↓ | -$242.38M↓ | -$226.22M |
| Net Income | -$284.30M↑ | -$320.62M↓ | -$246.51M↓ | -$212.83M↓ | -$166.57M |
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococca...